Skip to main content

Table 2 Objective response (RECIST version 1.1)

From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

  n %
Number of patients evaluated 16  
 CR 0 0
 PR 0 0
 SD 9 56.3
 PD 7 43.7
  1. RECIST response evaluation criteria in solid tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease.